SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: Linda Kaplan who wrote (5227)8/14/1998 9:26:00 PM
From: Claud B  Read Replies (1) | Respond to of 7041
 
<<<Maybe he's listening to the same untruths as some of our board
members.>>>

I think you meant "bored" members.

<<<ZONA was mentioned favorably, erroneously, >>>>

You mean he made a mistake?? Maybe he did his homework, unlike you.

<<<< Vasomax should have the SAME contraindications as Viagra,>>>>

Now who's posting "false hype?"

tick, tick, tick.



To: Linda Kaplan who wrote (5227)8/15/1998 6:31:00 AM
From: Peter Kerling  Respond to of 7041
 
Thanks Linda,

that might been the reason for the current delay in stock price
decline.

$17 - $19 is a short term support level for some weeks. I expect
this stock to fall to $12 in a few weeks. And after 3Q earnings release there will be a price target of $8.

Peter



To: Linda Kaplan who wrote (5227)8/17/1998 10:34:00 PM
From: Mkilloran  Read Replies (1) | Respond to of 7041
 
linda...the race in the ED marketplace will be more interesting a few years down the road. Not sure Zona will ever make it out of the starting gate to join the race.

But VVUS is working on the future to jump ahead of Viagra.
R&D work at Albert Einstein Medical Center in NYC funded by Vivus.
hot off the internet...paper edition being published at the end of this month.
#reply-5519555